Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu
- 1 February 2019
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 31 (2) , 260-266
Abstract
Objective Hepatitis C virus (HCV), cirrhosis, and HCV medications including direct-acting antivirals (DAAs) ±ribavirin may all influence the metabolic milieu. While interferon-based regimens improve glucose tolerance, evidence is limited on DAAs. Cases of elevated lactate have recently been reported in patients treated with DAAs, and lactic acidosis is a known complication of antivirals used to treat hepatitis B virus and HIV. Patients and methods Measures were evaluated at baseline, week 4, end of treatment, and 12–24 weeks after treatment. Mixed-effects modeling was used to determine factors influencing glucose and lactate over time. Results In total, 442 patients were treated (mean age 56, 65% male, 72% genotype 1, 48% cirrhotic). Glucose did not change on or after DAA treatment from baseline (P=0.51) aside from those with untreated diabetes, which declined (P=0.02). Overall, there was a decline in lactate following HCV treatment (mean 2.4–2.1 mmol/l; P<0.001). Lactate initially increased on treatment and then decreased after treatment completion in male patients treated with ribavirin. This pattern was not observed in other groups. There was no evidence of lactic acidosis with HCV nucleotide use. Conclusion Distinct glucose and lactate trajectories were identified without evidence of DAA metabolic toxicity. HCV treatment does not improve random glucose levels aside from perhaps in untreated diabetic patients.Keywords
This publication has 52 references indexed in Scilit:
- Mitochondrial Abnormalities in Patients with HIV-HCV Co-infection as Compared to Patients with HCV Mono-infectionHIV Research & Clinical Practice, 2011
- Hepatitis C Virus Infection and Its Clearance Alter Circulating LipidsHepatology, 2009
- Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patientsHepatology Research, 2009
- Hepatitis C infection and risk of diabetes: A systematic review and meta-analysisJournal of Hepatology, 2008
- Prognostic impact of lactate in acute liver failureLiver Transplantation, 2007
- A High Incidence of Lactic Acidosis and Symptomatic Hyperlactatemia in Women Receiving Highly Active Antiretroviral Therapy in Soweto, South AfricaClinical Infectious Diseases, 2007
- Hepatitis C Virus Infection and Human Pancreatic β-Cell DysfunctionDiabetes Care, 2005
- Lactic acidosis in HIV infected patients: a systematic review of published casesSexually Transmitted Infections, 2003
- Effect of Treatment With Peginterferon or Interferon Alfa–2B and Ribavirin on Steatosis in Patients Infected With Hepatitis CHepatology, 2003
- Red Blood Cell Transketolase Activity and the Effect of Thiamine Supplementation in Patients with Chronic Liver DiseaseScandinavian Journal of Gastroenterology, 1978